A Meta-Analysis of Cardiovascular Outcomes in Patients with Hypercholesterolemia Treated with Inclisiran

Pro-protein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are currently a class 1 recommendation for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients judged to be at very high risk for future ASCVD events in addition to maximally tolerated statins and ezetimibe.1 Recently, Inclisiran, a chemically synthesized small interfering RNA therapeutic agent that reduces hepatic synthesis of PCSK9 was developed with the intent to reduce plasma low-density lipoprotein-cholesterol (LDL-C) levels.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research